After rising 10.2% on Friday, investors could see further gains in the share price of Relief Therapeutics Holding (OTCMKTS:RLFTF) today. The little-known Swiss biopharmaceutical developer reported good news Monday on the results of clinical trials of its respiratory-failure treatment, Zyesami. And what’s good for RLFTF stock is already showing in the shares of its trial collaborator’s proposed SPAC partner.
That collaborator, NeuroRx, agreed in December to a merger with blank-check company Big Rock Partners (NASDAQ:BRPA). Shares of the special purpose acquisition company were up more than 34% in this morning’s pre-market activity following a similar gain on Friday.
The NeuroRx-Relief Therapeutics collaboration is seeking to bring to market the first therapeutic to demonstrate recovery and survival from Covid-19-related respiratory failure. Having met the primary endpoints in the trials, the effort will now be seeking emergency-use authorization from the U.S. Food and Drug Administration.
RLFTF Stock Has Taken Hit in Recent Weeks
RLFTF stock’s big gain on Friday were a relief to investors who’ve seen their shares lose 21% of their value in recent weeks after a one-day surge in the wake of NeuroRx’s announcement last month that its Phase 2b/3 trial of the RLF-100 compound demonstrated a range of benefits in discharged patients recovering from respiratory failure.
As the fate of the Swiss company seems tied up in its partnership with soon-to-be BRPA-owned NeuroRx, investor interest is shifting from vaccine developers to treatment makers and therapeutics firms. Long-haul Covid-19 could be a health crisis post-pandemic.
On Penny Stocks and Low-Volume Stocks: With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That’s because these “penny stocks” are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that InvestorPlace.com’s writers disclose this fact and warn readers of the risks.
Read More: Penny Stocks — How to Profit Without Getting Scammed
On the date of publication, Robert Lakin did not have (either directly or indirectly) any positions in the securities mentioned in this article.
InvestorPlace contributor Robert Lakin is a veteran financial writer and editor, following fintech, agtech and property tech startups.